Peptides vs SSRIs for Depression and Anxiety: Expert Psychiatrist Explains

Published: March 19, 2026 | By: Dr. Baghel | Category: Peptide Therapy

Peptides vs SSRIs Depression Anxiety: A Psychiatrist Who Prescribes Both Explains

The internet has decided that peptides and SSRIs are enemies. Wellness influencers frame it as “natural peptides” vs. “Big Pharma antidepressants.” Psychiatrists dismiss peptides as unproven. Peptide clinics dismiss SSRIs as outdated.

When a peptide’s human evidence is real but thin, the honest move is to say exactly how thin. DSIP is a clear case, covered in my guide to the DSIP peptide.

Semax is one of the peptides people ask about most, and its legal status is more restrictive than the marketing suggests. I cover it in is semax legal.

For where peptides fit among the proven options, see our guide to depression treatment in North Carolina.

Both sides are wrong. If you’re a patient caught in the middle, the tribalism is actively unhelpful.

I prescribe SSRIs, and I’ll prescribe compounded peptides like Semax and Selank if they become legally available. I’m board-certified in psychiatry by the ABPN, credentialed with 503A compounding pharmacies, and I evaluate both categories of treatment through the same lens: what does the evidence show, what are the risks, and what actually works for the patient sitting in front of me?

For the bigger picture on how metabolism shapes mood and anxiety, see my overview of metabolic psychiatry.

This article is for the person who’s tried SSRIs and feels stuck, or who’s curious about peptides but doesn’t want to abandon evidence-based care. It’s not a sales pitch for either side. It’s the conversation I have with patients across North Carolina every week via telehealth across North Carolina.

For a detailed breakdown of how catecholamine signaling relates to psychiatric treatment, see ADHD: Pathophysiology, Treatment Mechanisms, and Emerging Research.

For patients in North Carolina who are ready to explore peptide therapy with a board-certified psychiatrist, visit the peptide therapy service page for pricing, the evaluation process, and how to schedule a free consultation.

---

How SSRIs Actually Work (and Where They Fall Short)

SSRIs (selective serotonin reuptake inhibitors) like sertraline, escitalopram, and fluoxetine increase serotonin availability in the synapse by blocking its reabsorption. They’re the most prescribed psychiatric medications in the world, and for good reason: large-scale clinical trials demonstrate efficacy for depression and multiple anxiety disorders.

They have decades of safety data. Insurance covers them. They’re inexpensive.

Here’s where the story gets complicated.

The “chemical imbalance” theory that popularized SSRIs in the 1990s has been substantially challenged. A major 2022 umbrella review in Molecular Psychiatry found no consistent evidence that low serotonin levels cause depression (Moncrieff et al., 2022). SSRIs work for many patients, but probably not through the simple mechanism we were originally told.

More practically: about one-third of patients with depression don’t achieve remission on their first SSRI. Side effects cause a significant number of patients to discontinue treatment.

Sexual dysfunction is the most common complaint, with incidence rates ranging from 58% to 73% depending on the specific SSRI in prospective studies using validated questionnaires (Montejo et al., 2001). Weight gain, emotional blunting, and insomnia round out the list. For some anxiety subtypes, SSRIs provide partial relief at best.

None of this means SSRIs are bad medicine. It means they’re one tool, not the only tool. The patients sitting in my office asking about peptides are usually the ones for whom SSRIs haven’t been enough. SSRIs were marketed as correcting a serotonin deficit, but recent research has challenged this explanation.

Low testosterone can produce the same low mood, fatigue, and brain fog that often get treated as depression, so a proper low-testosterone evaluation belongs in the workup for men who feel stuck on an SSRI.

How Peptides Approach Depression and Anxiety Differently

The peptides most relevant to psychiatric treatment, specifically Semax and Selank, work through different pathways than SSRIs.

Semax increases brain-derived neurotrophic factor (BDNF), a protein critical for neuroplasticity. In rat hippocampus studies, a single intranasal dose of Semax produced a 1.4-fold increase in BDNF protein levels and a 3-fold increase in BDNF mRNA expression (Dolotov et al., 2006).

Low BDNF is consistently associated with depression. Interestingly, one of the downstream effects of SSRIs (weeks into treatment) is also BDNF upregulation. Semax appears to get there through a more direct route.

Selank modulates GABA and serotonin systems to reduce anxiety without sedation or cognitive impairment. In a clinical trial of 62 patients with generalized anxiety disorder, Selank’s anxiolytic effect was comparable to the benzodiazepine medazepam, but with additional antiasthenic and psychostimulant benefits and no dependence risk (Zozulia et al., 2008).

BPC-157 has anti-inflammatory and gut-healing properties. The gut-brain axis is increasingly recognized as relevant to depression and anxiety. Chronic gut inflammation can drive neuroinflammation, which can drive psychiatric symptoms. BPC-157 targets the gut side of that equation.

The key difference: SSRIs manipulate neurotransmitter levels directly. Peptides tend to work upstream, supporting the brain’s own regulatory systems (neuroplasticity, inflammation control, stress resilience) rather than forcing a specific chemical change.

Learn more about GLP-1s and the gut-brain axis.

SSRIs vs Peptides: Side-by-Side Comparison

Factor	SSRIs	Peptides (Semax, Selank, BPC-157)
Primary mechanism	Block serotonin reuptake in synapse	BDNF upregulation, GABA modulation, anti-inflammatory
FDA approval	Yes, for multiple psychiatric conditions	No (approved in Russia; not FDA-evaluated)
Evidence base	Decades of large-scale RCTs	Smaller clinical trials, primarily Russian research
Onset of effect	4 to 8 weeks for full effect	Days to weeks (varies by peptide)
Sexual dysfunction	58% to 73% incidence	Not reported in clinical literature
Weight gain	Common, especially long-term	Not reported
Emotional blunting	Frequently reported	Not reported
Dependence risk	Discontinuation syndrome on stopping	No dependence reported
Insurance coverage	Typically covered	Not covered
Availability	Any pharmacy	503A compounding pharmacies only
Monthly cost	$4 to $30 (generic)	Varies; requires prescriber credentialed with compounding pharmacy
Can be combined	Yes, with monitoring	Yes, with monitoring (serotonergic overlap requires oversight)

The Honest Comparison: What Each Does Better

Where SSRIs have the advantage:

Decades of large-scale, FDA-scrutinized clinical trial data. Proven efficacy for major depressive disorder, generalized anxiety disorder, panic disorder, OCD, and PTSD.

Covered by insurance. Available at any pharmacy. Extensively studied for drug interactions and long-term safety. If you need a medication that a new provider can review, understand, and continue without specialized knowledge, SSRIs are the safest default.

Where peptides have the advantage:

Different mechanism of action, which matters when SSRIs haven’t worked. Generally fewer side effects: no sexual dysfunction, no weight gain, no emotional blunting in clinical reports to date.

Faster onset for some patients. Selank’s anxiolytic effects can be noticed within days vs. 4 to 8 weeks for SSRIs. They address neuroplasticity and neuroinflammation directly. And they can be used alongside SSRIs as augmentation rather than replacement.

Where peptides fall short:

Not FDA-approved. Smaller clinical trials, primarily from Russian research groups. Limited long-term safety data in Western populations.

Not available at your local pharmacy. Require a physician credentialed with compounding pharmacies. Insurance won’t cover them.

And critically: the unregulated market is full of products with no quality controls, making sourcing a real safety concern. I wrote about the current regulatory environment around peptides in detail if you want the full picture.

The Question Nobody Is Asking: Why Not Both?

This is the part that the “peptides vs. SSRIs” framing gets completely wrong. In clinical practice, the question is rarely either/or. It’s about sequencing, combination, and matching the intervention to the specific patient.

If Semax and Selank become legal to compound, I’d expect to use them alongside an SSRI. Semax may help cognitive symptoms the SSRI doesn’t touch, and Selank may help anxiety that persists while the SSRI handles baseline mood.

The only way to determine the right approach is a comprehensive evaluation that considers your specific diagnoses, medication history, side effect profile, treatment goals, and overall health picture. A blanket statement that “peptides are better than SSRIs” or “SSRIs are the only legitimate option” is equally useless.

This is why the prescriber’s training matters. A med spa can sell you peptides. A traditional psychiatrist can prescribe SSRIs. Finding a psychiatrist who understands both and can build an integrated plan is the actual value proposition, and it’s something I do for patients throughout North Carolina via secure telehealth.

Patients interested in exploring whether peptides could complement or eventually reduce their current psychiatric medications can learn more about Dr. Baghel’s peptide therapy services in North Carolina, including pricing and how to schedule an evaluation.

Peptide-based approaches are one part of the broader landscape of emerging mental health treatments including psychedelic therapy, which is accelerating toward clinical availability for treatment-resistant conditions.

What About Safety? The Risks Nobody Wants to Talk About

SSRI risks that are well-documented:

Sexual dysfunction (58% to 73% of patients in prospective studies). Weight gain. Emotional blunting. Discontinuation syndrome (withdrawal-like symptoms when stopping).

Serotonin syndrome (rare but serious, usually from drug interactions). Increased suicidal ideation in young adults during the first weeks of treatment (black box warning).

Peptide risks that are less well-characterized:

Limited long-term safety data in Western clinical populations. Potential for contamination or incorrect dosing from unregulated sources.

Possible interactions with serotonergic or GABAergic medications that haven’t been studied in formal drug interaction trials. Nasal irritation, headache, and dizziness are the most commonly reported side effects in clinical use.

I present both risk profiles to patients. I also emphasize that the risk of peptides is dramatically different depending on sourcing. A peptide from a licensed 503A compounding pharmacy with batch testing is a fundamentally different product than a vial purchased from a “research chemical” website. If I prescribe peptides, they’ll come only from that kind of pharmacy.

Who Should Consider Peptides Alongside (or Instead of) SSRIs

Based on the evidence so far, these patients would be the most likely to benefit from adding peptide therapy:

Those with treatment-resistant depression who have failed two or more adequate SSRI trials.

Those who can’t tolerate SSRI side effects, particularly sexual dysfunction or emotional blunting.

Those with comorbid anxiety and cognitive impairment where SSRIs address mood but not cognition.

Those with neuroinflammatory markers or gut-brain axis dysfunction contributing to psychiatric symptoms.

Those with PTSD who are in active psychotherapy and need additional neurobiological support.

The $250/month plan at Baghel Psychiatry covers up to four visits for psychiatric care, TRT, and medical weight loss. If peptides become legally available, the plan will include peptide therapy visits. Monthly plans cover Dr. Baghel’s clinical services. Labs and medications are separate costs paid by the patient.

For patients with treatment-resistant depression, peptide therapy represents an emerging option after standard approaches have been exhausted.

---

Frequently Asked Questions

Can I take peptides and an SSRI at the same time?

In many cases, yes. Semax and Selank work through different mechanisms than SSRIs and are commonly used alongside them. However, any combination requires physician oversight because both Selank and SSRIs influence serotonin pathways. I evaluate potential interactions on a case-by-case basis and monitor patients accordingly. Never combine medications or peptides without consulting your prescribing psychiatrist.

Are peptides a “natural” alternative to antidepressants?

The word “natural” doesn’t mean much in pharmacology. Semax and Selank are synthetic peptides derived from naturally occurring hormone fragments. SSRIs are synthetic molecules designed to modulate naturally occurring neurotransmitter systems. Both are pharmaceutical interventions. The relevant questions are: what does the evidence show, what are the side effects, and which mechanism matches your specific clinical picture? I evaluate both on the same evidence-based criteria. For a deeper look at Semax and Selank specifically, read my clinical breakdown of how these peptides work.

Why doesn’t my current psychiatrist offer peptides?

Most psychiatrists were not trained in peptide therapy and their practices are not credentialed with compounding pharmacies. This isn’t a failing on their part. Peptide therapy for psychiatric applications is a relatively new area that sits at the intersection of psychiatry, endocrinology, and integrative medicine. It requires specific pharmaceutical relationships and a willingness to work with emerging evidence. Most traditionally trained psychiatrists are excellent clinicians who stick to well-established treatments, and there’s nothing wrong with that approach.

Should I stop my SSRI and switch to peptides?

Do not stop your SSRI abruptly. Discontinuation syndrome is real and can cause significant discomfort and symptom rebound. If you’re interested in exploring whether peptides could play a role in your treatment, the first step is a comprehensive evaluation to determine whether your current medications are working, partially working, or not working. Any transition away from an SSRI, if appropriate, would be gradual and monitored. In many cases, peptides are added alongside existing medications, not substituted for them.

Can I get peptide therapy via telehealth in North Carolina?

Semax and Selank aren’t eligible for 503A compounding today, so I don’t prescribe them yet. If they become legally available, I plan to evaluate patients by video and prescribe where the workup supports it. Book a free consultation to go over the treatments available to you now.

How do I know if peptides are right for me?

You need a comprehensive psychiatric evaluation, not a blog post. The answer depends on your specific diagnoses, treatment history, medication response, lab results, and goals. Schedule a free consultation and we’ll talk through whether peptide therapy makes sense for your situation.

---

References

1. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28(8):3243-3256. PMID: 35854107

2. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry. 2001;62(Suppl 3):10-21. PMID: 11229449

3. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. PMID: 16996037

4. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(4):38-48. PMID: 18454096

---

Disclaimer: This article is for educational purposes only and is not medical advice. Peptides discussed in this article are not FDA-approved for psychiatric indications. SSRIs are FDA-approved medications with established efficacy data. All treatment decisions require individualized evaluation by a licensed provider. Do not start, stop, or modify any medication without consulting a clinician who knows your medical history.